News Image

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Provided By GlobeNewswire

Last update: Jan 2, 2025

SAN DIEGO, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that on January 2, 2025, the Compensation Committee of Zentalis’ Board of Directors granted non-qualified stock options to purchase an aggregate of 45,000 shares of the Company’s common stock to two newly hired employees. The stock options were granted under the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan (2022 Inducement Plan) as an inducement material to each such individual’s entering into employment with Zentalis in accordance with Nasdaq Listing Rule 5635(c)(4).

Read more at globenewswire.com

ZENTALIS PHARMACEUTICALS INC

NASDAQ:ZNTL (2/21/2025, 8:00:02 PM)

After market: 2.28 -0.04 (-1.72%)

2.32

-0.15 (-6.07%)



Find more stocks in the Stock Screener

ZNTL Latest News and Analysis

ChartMill News Image18 days ago - ChartmillHere are the top movers in Wednesday's session.

Looking for insights into the US markets one hour before the close of the markets on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Mentions: FMC CPIX TNXP ACB ...

Follow ChartMill for more